Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28748927 | 0.82 | L3MBTL1 (0.60) | L3MBTL1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL28748838 | 0.82 | L3MBTL1 (0.60) | L3MBTL1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL2539306 | 0.81 | AOC3 (0.50) | AOC3ADRB3 | |
| SCHEMBL2543561 | 0.81 | AOC3 (0.50) | AOC3ADRB3 | |
| SCHEMBL2537512 | 0.81 | CHRM2 (0.52) | L3MBTL1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL5157644 | 0.81 | ADRB3 (0.45) | ADRB3 | |
| SCHEMBL2541814 | 0.81 | ADRB3 (0.45) | ADRB3 | |
| SCHEMBL2544966 | 0.81 | ADRB3 (0.45) | ADRB3 | |
| SCHEMBL2541606 | 0.79 | LMNA (0.48) | L3MBTL1AOC3KDM4E | |
| SCHEMBL5159743 | 0.79 | LMNA (0.48) | L3MBTL1AOC3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044245-B2 | Method for the preparation of optically active 2-sulfonyloxy-1-phenylethanol derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-10-25 | — | — | US | disclosed |
| US-20100063317-A1 | METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE 2-SULFONYLOXY-1-PHENYLETHANOL DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063317-A1 | METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE 2-SULFONYLOXY-1-PHENYLETHANOL DERIVATIVES | FOXO1, ENO1, SULT1A1 | L3MBTL1 4788/4885AOC3 1932/4885CHRM2 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.